Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04552886 · ClinicalTrials.gov registry record · Phase 1
Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma
A Phase 1 study of Glioblastoma, sponsored by The Cooper Health System.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 2
- Study locations
NCT04552886 is a Phase 1 study of Glioblastoma that has completed, run by The Cooper Health System. The registered enrollment target is 17 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (84% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT04552886, a Phase 1 study of Glioblastoma, has completed, sponsored by The Cooper Health System.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 2
- Study locations
Study Summary
Effective treatments are desperately needed for glioblastoma (GBM) patients. This phase I clinical trial assesses the safety of a novel personalized dendritic-cell vaccine administered to GBM patients shortly after completing standard-of-care treatments. Secondary outcomes will evaluate patient progression-free survival and overall survival.
Conditions Studied
Interventions
- BIOLOGICAL TH-1 Dendritic Cell Immunotherapy
Study Locations (2)
New Jersey
- Cooper University Hospital - Camden
Texas
- Memorial Hermann- Texas Medical Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2021-10-11 |
| Est. Completion | 2023-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04552886
The ClinicalTrials.gov registry entry for NCT04552886 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (84% lower). The listed sponsor is The Cooper Health System, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which TH-1 Dendritic Cell Immunotherapy is the first listed.
NCT04552886 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New Jersey, Texas.
Frequently Asked Questions
What is clinical trial NCT04552886 about?
NCT04552886 is a clinical study titled "Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma". Effective treatments are desperately needed for glioblastoma (GBM) patients. This phase I clinical trial assesses the safety of a novel personalized dendritic-cell vaccine administered to GBM patients shortly after completing standard-of-care treatments. Secondary outcomes will evaluate patient prog...
What is the current status of trial NCT04552886?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2021-10-11. Estimated completion is 2023-12-01.
What conditions does trial NCT04552886 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT04552886?
The interventions under investigation include: TH-1 Dendritic Cell Immunotherapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT04552886?
This trial is sponsored by The Cooper Health System, which has 39 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04552886 being conducted?
This trial has 2 study locations across New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.